SNIP REJECTS INDUSTRY AGREEMENT
The French pharmaceutical industry SNIP has rejected proposals relating to the modification of the pharmaceutical industry collective agreement and is currently in new negotiations with other unions and the French Ministry for Work to sign the accord.
SNIP has indicated that a protocol for agreement has been drawn up focussing on the following points:
- agreement on three projects relating to professional development and education, providing amendments are made, which the unions had previously refused to endorse; - agreement on the need for continued updating of the old collective agreement; - formal establishment of groups to undertake this procedure within the framework of negations. Any failure to agree will result in the questioning of the durability of the agreement.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze